Private company

Syros Pharmaceuticals, Inc.

In its 2024 annual report the company says: “We are a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.”5 It is headquartered in Cambridge, United States.2

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersCambridge, United States2
  • Incorporated inDE3
  • Business address35 Cambridge Park Drive, Cambridge, Ma 021403
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300512PURS7IGVT962
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 50634982

See how the biggest companies compare on our leaderboards

We are a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, we are advancing tamibarotene, a selective retinoic acid receptor alpha, or RARα, agonist for which we are conducting SELECT-MDS-1, a Phase 3 clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome, or HR-MDS, and for which we are conducting SELECT-AML-1, a randomized Phase 2 clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia, or AML, who are not suitable candidates for standard intensive chemotherapy.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-1298.2%Operating margin6
-1656.3%Net margin6
-33.2%Revenue growth, 20236
-987.7%Return on equity6
2.07×Debt to equity6
-$110.0MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Research and development95¢$108.2M
  • Interest5¢$5.1M
  • Income tax0¢$1.0K

Out of $9.9M in revenue.6 The company lost money this year.

Financial statements

Revenue789106$9.9M in 2023+802% since 2017
0$10.0M$20.0M$30.0M2017: $1.1M$1.1M20172018: $2.0M$2.0M2018+86%2019: $2.0M$2.0M2019−3%2020: $15.1M$15.1M2020+662%2021: $23.5M$23.5M2021+56%2022: $14.9M$14.9M2022−37%2023: $9.9M$9.9M2023−33%
Operating income789106-$129.0M in 2023+136% since 2017
-$150.0M-$100.0M-$50.0M02017: -$54.7M-$54.7M20172018: -$64.3M-$64.3M2018+18%2019: -$77.7M-$77.7M2019+21%2020: -$82.3M-$82.3M2020+6%2021: -$99.4M-$99.4M2021+21%2022: -$135.9M-$135.9M2022+37%2023: -$129.0M-$129.0M2023−5%
Net income111213106-$164.6M in 2023+205% since 2017
-$200.0M-$150.0M-$100.0M-$50.0M02017: -$54.0M-$54.0M20172018: -$62.3M-$62.3M2018+15%2019: -$75.4M-$75.4M2019+21%2020: -$84.0M-$84.0M2020+11%2021: -$86.6M-$86.6M2021+3%2022: -$94.7M-$94.7M2022+9%2023: -$164.6M-$164.6M2023+74%
Fiscal year2017201820192020202120222023
Revenue$1.1M7$2.0M8$2.0M9$15.1M10$23.5M10$14.9M6$9.9M6
Research and development$41.9M7$50.2M8$58.2M9$76.1M10$99.9M10$111.9M6$108.2M6
Operating expenses$122.9M10$150.8M6$138.9M6
Operating income-$54.7M7-$64.3M8-$77.7M9-$82.3M10-$99.4M10-$135.9M6-$129.0M6
Interest$1.0K8$72.0K9$1.8M10$3.9M10$4.1M6$5.1M6
Income tax$7.0K7$24.0K8$28.0K9$4.0K10$1.0K10$3.0K6$1.0K6
Net income-$54.0M11-$62.3M12-$75.4M13-$84.0M10-$86.6M10-$94.7M6-$164.6M6
Earnings per share-$18.2010-$13.8410-$7.496-$5.816
Earnings per share (diluted)-$18.2010-$13.8410-$7.496-$5.816
Shares (weighted, basic)6.3M shares1012.6M shares628.3M shares6
Shares (weighted, diluted)6.3M shares1012.6M shares628.3M shares6

Compare Syros Pharmaceuticals, Inc. with another company

Corporate structure

Syros Pharmaceuticals, Inc. sits at the top of its group. 5 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Syros Pharmaceuticals, Inc.

  • Samsara BioCapital, L.P. Filed SCHEDULE 13D/A on Syros Pharmaceuticals, Inc., latest Mar 27, 2025 (3 filings since Oct 20, 2023)
  • Avidity Partners Management LP Filed SCHEDULE 13G/A on Syros Pharmaceuticals, Inc., latest Feb 14, 2025 (5 filings since Sep 20, 2022)
  • Deep Track Capital, LP Filed SCHEDULE 13G/A on Syros Pharmaceuticals, Inc., latest Feb 14, 2025 (2 filings since Sep 19, 2022)
  • Point72 Asset Management, L.P. Filed SCHEDULE 13G/A on Syros Pharmaceuticals, Inc., latest Feb 14, 2025 (2 filings since Jan 2, 2024)
  • ADAGE CAPITAL PARTNERS GP, L.L.C. Filed SCHEDULE 13G/A on Syros Pharmaceuticals, Inc., latest Feb 12, 2025 (3 filings since Jan 25, 2023)
  • Invus Global Management, LLC Filed SCHEDULE 13G/A on Syros Pharmaceuticals, Inc., latest Feb 12, 2025 (3 filings since Aug 2, 2024)
  • Bain Capital Life Sciences Fund II, L.P. Filed SC 13G/A on Syros Pharmaceuticals, Inc., latest Nov 14, 2024 (4 filings since Feb 14, 2022)
  • Blue Owl Capital Filed SC 13G/A on Syros Pharmaceuticals, Inc., latest Nov 14, 2024 (2 filings since Feb 14, 2024)
  • Ally Bridge MedAlpha Master Fund L.P. Filed SC 13G/A on Syros Pharmaceuticals, Inc., latest Feb 13, 2024 (3 filings since Feb 11, 2022)
  • Artal International S.C.A. Filed SC 13G/A on Syros Pharmaceuticals, Inc., latest Feb 9, 2024 (3 filings since Feb 11, 2022)
  • FMR LLC Filed SC 13G/A on Syros Pharmaceuticals, Inc., latest Nov 10, 2022 (3 filings since Feb 9, 2022)
  • Amova Asset Management Americas, Inc. Filed SC 13G/A on Syros Pharmaceuticals, Inc., latest Feb 14, 2022
  • Syros Pharmaceuticals, Inc. Cambridge, Massachusetts, United States
    • Syros Pharmaceuticals (Ireland) Limited Subsidiary · Ireland
    • Syros Securities Corporation Subsidiary · Massachusetts, United States
    • Tyme Technologies, Inc. Subsidiary · Delaware, United States
    • Tyme, Inc. Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Syros Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$14.9M6 Dec 31, 2023$23.9M6 Dec 31, 2022−37.5%
Accumulated depreciation$7.6M6 Dec 31, 2023$12.6M6 Dec 31, 2022−39.2%
Property and equipment, net$7.3M6 Dec 31, 2023$11.4M6 Dec 31, 2022−35.7%
Finance-lease assets$76.0K6 Dec 31, 2022$337.0K10 Dec 31, 2021−77.4%
Operating-lease assets (leased space)$12.2M6 Dec 31, 2023$13.2M6 Dec 31, 2022−7.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$139.5M6 Dec 31, 2023$167.5M6 Dec 31, 2022−16.7%
Marketable securities, current$34.8M6 Dec 31, 2022$38.1M10 Dec 31, 2021−8.5%

Leadership

Who has led Syros Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Nancy A. Simonian2016–2023
  2. Conley Chee2023–2024

President

  1. Nancy A. Simonian2016–2023
  2. Conley Chee2023–2024

Chief financial officer

  1. Joseph J. Ferra Jr.2018–2021
  2. Jason Haas2021–2024

Chief operating officer

  1. Kyle D. Kuvalanka2016–2017
20202025
Board members and other officers (25)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerConely C. Chee named Sep 21, 202246
  • Executive OfficerEric C. Olson named Sep 21, 202246
  • DirectorRichard A. Young named Sep 21, 202246

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Syros Pharmaceuticals (Ireland) Limited Ireland4
  • Syros Securities Corporation Massachusetts4
  • Tyme Technologies, Inc. Delaware4
  • Tyme, Inc. Delaware4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • LS22, Inc.Aug 22, 2012 to Aug 22, 20123

Timeline

  1. Mar 4, 20258-K Other events47
  2. Feb 28, 20258-K Listing notice or transfer; Executive or director change; Other events48
  3. Jan 8, 20258-K Listing notice or transfer49
  4. Dec 6, 20248-K Entered a material agreement50
  5. Nov 18, 20248-K Ended a material agreement; Debt or obligation accelerated; Exit or restructuring costs51
  6. Nov 13, 20248-K Debt or obligation accelerated; Other events52
  7. Sep 5, 20248-K Regulation FD disclosure53
  8. Aug 12, 20248-K Other events54
  9. Jun 6, 20248-K Executive or director change; Shareholder vote55
  10. Jan 8, 20248-K Regulation FD disclosure; Other events56
  11. Dec 19, 20238-K Entered a material agreement; Other events57
  12. Dec 6, 20238-K Regulation FD disclosure; Other events58
  13. Dec 5, 2023New chief executive Conley Chee becomes CEO18
  14. Jun 29, 2016New chief executive Nancy A. Simonian becomes CEO19
  15. Nov 9, 2011Founded Syros Pharmaceuticals, Inc. is founded2

Filings

288 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 32 major events, 119 insider forms, 35 large holders, 1 private raises, 88 other. The latest 20:

  1. Mar 27, 2025SCHEDULE 13D/A EDGAR
  2. Mar 20, 202515-12G EDGAR
  3. Mar 14, 2025144 EDGAR
  4. Mar 11, 2025EFFECT EDGAR
  5. Mar 11, 2025EFFECT EDGAR
  6. Mar 11, 2025EFFECT EDGAR
  7. Mar 11, 2025EFFECT EDGAR
  8. Mar 11, 2025EFFECT EDGAR
  9. Mar 11, 2025EFFECT EDGAR
  10. Mar 11, 2025EFFECT EDGAR
  11. Mar 11, 2025144 EDGAR
  12. Mar 10, 2025S-8 POS EDGAR
  13. Mar 10, 2025S-8 POS EDGAR
  14. Mar 10, 2025S-8 POS EDGAR
  15. Mar 10, 2025S-8 POS EDGAR
  16. Mar 10, 2025S-8 POS EDGAR
  17. Mar 10, 2025S-8 POS EDGAR
  18. Mar 10, 2025S-8 POS EDGAR
  19. Mar 10, 2025S-8 POS EDGAR
  20. Mar 10, 2025S-8 POS EDGAR

The 288 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 8 buys and 15 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 2, 2024Simonian Nancy ADirectorSale37,070$0.27$10.0KForm 4
Nov 25, 2024Simonian Nancy ADirectorSale134,713$0.27$36.4KForm 4
Nov 19, 2024Quirk Gerald EChief Legal & Compliance OfficSale46,657$0.22$10.3KForm 4
Nov 18, 2024Stephens KristinChief Development OfficerSale36,133$0.22$7.9KForm 4
Nov 18, 2024Roth DavidChief Medical OfficerSale12,099$0.20$2.4KForm 4
Nov 18, 2024Chee ConleyPresident & CEOSale134,797$0.20$27.0KForm 4
Nov 18, 2024Haas JasonChief Financial OfficerSale137,803$0.21$28.9KForm 4
Sep 12, 2024Haas JasonChief Financial OfficerBuy45,344$1.68$76.2KForm 4
Sep 11, 2024Haas JasonChief Financial OfficerBuy19,293$1.58$30.5KForm 4
Sep 11, 2024Chee ConleyPresident & CEOBuy50,000$1.71$85.5KForm 4
Sep 10, 2024Haas JasonChief Financial OfficerBuy35,363$1.55$54.8KForm 4
Sep 10, 2024Chee ConleyPresident & CEOBuy50,000$1.51$75.5KForm 4
Jun 28, 2024Young Richard ADirectorSale34,837$5.12$178.4KForm 4
Apr 3, 2024Roth DavidChief Medical OfficerSale10,451$4.95$51.7KForm 4
Apr 2, 2024Roth DavidChief Medical OfficerSale150$4.98$747Form 4
Dec 21, 2023AKKARAJU SRINIVASDirectorBuy904,977$4.42$4.0MForm 4
Dec 12, 2023Roth DavidChief Medical OfficerSale6,287$4.95$31.1KForm 4
Dec 6, 2023Roth DavidChief Medical OfficerSale6,287$3.95$24.8KForm 4
Jul 31, 2023Roth DavidChief Medical OfficerSale7,348$3.95$29.0KForm 4
Jul 17, 2023Olson Eric RChief Scientific OfficerSale689$3.50$2.4KForm 4

All 23 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Sep 16, 2022Raised $129.8 million in a private offering of equity Form D: 19 investors so far Form D

SEC filer profile

How Syros Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSyros Pharmaceuticals, Inc.1
  • CIK0001556263
  • Employer ID (EIN)45-37724601
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address35 Cambridge Park Drive, Cambridge, MA 021401
  • Phone617-744-13401
  • Shares outstanding26,832,457 as of Oct 24, 202416
  • Public float$58.6M as of Jun 30, 20236
  • On EDGAR sinceAug 22, 20121
  • Filings682 in all: 4 (248), 8-K (80), SC 13G/A (45), 3 (41), 10-Q (26), 144 (26), SC 13G (18), EFFECT (17)1
    All 52 form types

    4/A (13), CORRESP (13), 424B5 (12), UPLOAD (12), S-8 (11), S-8 POS (11), 10-K (8), DEF 14A (8), POS AM (8), DEFA14A (7), D (6), S-3 (6), CT ORDER (5), SC 13D (5), SCHEDULE 13G/A (5), 424B3 (4), 425 (4), SC 13D/A (4), 3/A (3), DRS/A (3), S-3/A (3), 10-Q/A (2), 5 (2), 8-K/A (2), ARS (2), DRSLTR (2), FWP (2), S-1 (2), 10-K/A (1), 15-12G (1), 25 (1), 424B4 (1), 8-A12B (1), 8-A12B/A (1), CERTNAS (1), D/A (1), DEL AM (1), DRS (1), PRE 14A (1), S-1/A (1), S-4 (1), S-4/A (1), S-4MEF (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 27, 2024
    Quarterly report (10-Q) Oct 31, 2024
    Proxy statement (DEF 14A) Apr 23, 2024
    Latest 8-K (8-K) Mar 4, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
    SEC EDGAROther events
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
    SEC EDGAROther events
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71